All News
Risankizumab Tops Competitor for Clinical Remission in Moderate-to-Severe CD
(MedPage Today) -- SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on risankizumab (Skyrizi) versus ustekinumab (Stelara), accord
Read MorePutting Diabetes Into Remission; Does Prehabilitation Work?
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech.
Read MoreMexico authorities order factory cleanup after Guardian toxic waste investigation
Inquiry uncovered health problems in neighborhood near Monterrey-area plant that processes US hazardous wasteMexican environmental regulators say they have discovered 30,000 tons of improperly stored
Read MoreThe Double-Edged Screen: Online Platforms Can Be a Force for Good for Kids
(MedPage Today) -- Children's online safety took center stage during a Senate hearing in early 2024, when Meta CEO Mark Zuckerberg apologized to concerned parents following mounting criticism of the
Read MoreAnti-ageing jabs – they can rejuvenate mice, but will they work on humans?
Senescent cells power the body’s ageing process, and scientists are developing treatments to annihilate themAt St Jude children’s research hospital in Memphis, Tennessee, an unusual clinical trial
Read MoreDirect Primary Care Cuts Out Insurers. Could It Gain Traction Under Trump?
(MedPage Today) -- Andrea Meneses stumbled on a direct primary care clinic because of a crisis.
Read MoreOpinion: The NIH’s drastic cut to indirect cost rates is a critical threat to U.S. research infrastructure
The drastic reduction in indirect costs is not a path to innovation or cost savings — it’s a threat to U.S.’s position as global leader in medical research.
Read MoreAstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?
When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibilityAt a tense meeting with senior civ
Read MoreTrump and Musk Bring Vast Aid Machinery to a Halt in Africa
The collapse of U.S.A.I.D. at the hands of President Trump and Elon Musk is already leaving gaping holes in vital health care and other services that millions of Africans rely on for their survival.
Read MoreA Swearing Expert Discusses the State of Profanity
Timothy Jay, a scholar in the science of swearing, has a few choice words about why we curse and how to cut back (if you want to).
Read More